Clinical Trial Update: Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac [Phase 2]

View source ↗

Summary

Phase II trial assessing safety and immunogenicity of the recombinant subunit tuberculosis vaccine GamTBvac has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• GamTBvac (recombinant subunit tuberculosis vaccine)

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: Healthy | Phase 2 | Status: COMPLETED